FDA accepts Aveo kidney cancer pill application

Legislation to limit cancer expenses

Patients suffering from rare and chronic diseases often face …

Former Marine felt cancer a payback

Ron Poirier couldn't escape the feeling that his cancer was …

Marine base exposed to toxic tap water

A simple test could have alerted officials that the drinking …

"Bionic Hand" opens new world

Man who lost his arm to cancer can now hold his daughter.

7 questions on cancer gene testing

Angelina Jolie's case highlights the importance of knowing …

Possible treatment for several cancer types

Updated: Wednesday, 28 Nov 2012, 5:04 PM EST
Published : Wednesday, 28 Nov 2012, 5:04 PM EST

The Associated Press

CAMBRIDGE, Mass. (AP) - Aveo Oncology said Wednesday that the Food and Drug Administration will complete a review of its cancer pill Tivopath by July 28.

Aveo and its partner Astellas Pharma Inc. want to market Tivopath as a treatment for advanced kidney cancer. The companies said the FDA accepted their application, and the agency will conduct a standard 10-month review. Astellas will pay Aveo $15 million now that the filing has been accepted.

Tivopath, or tivozanib, is a tablet intended to be taken once per day. The companies are also studying the drug as a treatment for other solid tumors, including cancers of the breast and colon.

FDA accepts Aveo kidney cancer pill application

Possible treatment for several cancer types

Site Tools